145 related articles for article (PubMed ID: 35117880)
1. Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients.
Li C; Lu F; Lei T; Yu H; Yang H
Transl Cancer Res; 2020 Sep; 9(9):5139-5146. PubMed ID: 35117880
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy.
Li C; Lu F; Lei T; Yu H; Chen X; Peng S; Han S; Yang H
BMC Cancer; 2020 Aug; 20(1):742. PubMed ID: 32770971
[TBL] [Abstract][Full Text] [Related]
3. Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis.
Liu C; Zhang X; Zhu Y; Wei J; Ye X; Yang C; Tong H; Mai W; Yang M; Qian J; Mao L; Meng H; Jin J; Yu W
Ann Hematol; 2023 Sep; 102(9):2387-2395. PubMed ID: 37278748
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
Huang YC; Liu CJ; Liu CY; Pai JT; Hong YC; Teng HW; Hsiao LT; Chao TC; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Yu YB; Tzeng CH
Ann Hematol; 2011 Oct; 90(10):1145-51. PubMed ID: 21647583
[TBL] [Abstract][Full Text] [Related]
6. Immunochemotherapeutic increase of peripheral absolute monocyte count predicts interstitial pneumonia in lymphoma patients.
Lang M; Yu J; Wang X; Song Z; Li L; Qiu L; Zhang H
Hematol Oncol; 2018 Dec; 36(5):779-785. PubMed ID: 30144117
[TBL] [Abstract][Full Text] [Related]
7. Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma.
Liu WP; Wang XP; Zheng W; Xie Y; Tu MF; Lin NJ; Ping LY; Ying ZT; Zhang C; Deng LJ; Ding N; Wang XG; Song YQ; Zhu J
Ann Hematol; 2018 Jan; 97(1):133-139. PubMed ID: 29086010
[TBL] [Abstract][Full Text] [Related]
8. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab.
Kurokawa T; Kaya H; Yoshida T
J Clin Exp Hematop; 2010; 50(2):159-62. PubMed ID: 21123974
[TBL] [Abstract][Full Text] [Related]
9. Multiple blood parameters may serve as a warning to immunochemotherapy-related interstitial lung disease in B-cell lymphoma.
Xia F; Liu H; Zhang H; Ping N; Wang P; Jin Z; Zhu J; Qu C
Ann Palliat Med; 2021 Sep; 10(9):9660-9668. PubMed ID: 34628891
[TBL] [Abstract][Full Text] [Related]
10. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma.
Katsuya H; Suzumiya J; Sasaki H; Ishitsuka K; Shibata T; Takamatsu Y; Tamura K
Leuk Lymphoma; 2009 Nov; 50(11):1818-23. PubMed ID: 19863173
[TBL] [Abstract][Full Text] [Related]
11. Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphoma.
Kato H; Yamamoto K; Taji H; Oki Y; Chihara D; Seto M; Kagami Y; Morishima Y
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):483-9. PubMed ID: 21978956
[TBL] [Abstract][Full Text] [Related]
12. Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.
Hashimoto K; Kobayashi Y; Asakura Y; Mori M; Azuma T; Maruyama D; Kim SW; Watanabe T; Tobinai K
Leuk Lymphoma; 2010 Oct; 51(10):1816-21. PubMed ID: 20919860
[TBL] [Abstract][Full Text] [Related]
13. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
[TBL] [Abstract][Full Text] [Related]
14. Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab.
Salmasi G; Li M; Sivabalasundaram V; Panzarella T; Tsang R; Kukreti V; Crump M; Kuruvilla J
Leuk Lymphoma; 2015 Jun; 56(6):1659-64. PubMed ID: 25356925
[TBL] [Abstract][Full Text] [Related]
15. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma.
Liu X; Hong XN; Gu YJ; Wang BY; Luo ZG; Cao J
Leuk Lymphoma; 2008 Sep; 49(9):1778-83. PubMed ID: 18798110
[TBL] [Abstract][Full Text] [Related]
16. [Pneumocystis pneumonia prophylaxis with low-dose trimethoprim/sulfamethoxazole during rituximab-containing chemotherapy].
Shimizu R; Sakemura R; Iwata S; Hayakawa H; Miyao K; Kajiguchi T
Rinsho Ketsueki; 2019; 60(5):365-371. PubMed ID: 31167996
[TBL] [Abstract][Full Text] [Related]
17. Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival.
Wei W; Zhu Y; Tang J; Xu C; Li J; He S; Zhang Z; Wu P; Luo L; Guo Q; Li F; Ren Y; Yu S; Li R; Li L
Leuk Res; 2021 Dec; 111():106688. PubMed ID: 34450501
[TBL] [Abstract][Full Text] [Related]
18. [Interstitial pneumonia in patients with diffuse large B-cell lymphoma receiving RCHOP and RCDOP regimens].
Meng YN; Wang S; Shi Q; Xu PP; Cheng S; Wang L; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1015-1020. PubMed ID: 32023732
[No Abstract] [Full Text] [Related]
19. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
20. Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy.
Kim T; Choi SH; Kim SH; Jeong JY; Woo JH; Kim YS; Sung H; Kim MN; Yoon DH; Suh C; Lee SO
Ann Hematol; 2013 Jan; 92(2):231-8. PubMed ID: 23053189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
